Trillions of microbes live in and on you. They digest your food, train your immune system, and send chemical messages to your brain. The science is thrilling. The supplement industry is ahead of the evidence — and your gut deserves better than hype.
Published 14 October 2026 · 06:00 GMT
Last updated: October 2026
Trillions of microbes live in and on you. They digest your food, train your immune system, and send chemical messages to your brain. The science is thrilling. The supplement industry is ahead of the evidence — and your gut deserves better than hype.
You are not one organism. You are a walking ecosystem. In your gut alone live trillions of bacteria, archaea, viruses and fungi — a community so dense and diverse that its collective genome dwarfs your own. They arrived at birth, were shaped by your first foods, your antibiotics, your environment, and they have been with you ever since, digesting what you cannot, manufacturing vitamins, training your immune system, and communicating with organs you would never suspect — including your brain. To understand human biology without the microbiome is like understanding a forest by studying only the trees and ignoring the soil, the fungi and the pollinators.
The revolution began quietly, with sequencing. Until the 2000s, microbiology studied what it could grow in a petri dish — a small minority of microbes. Metagenomic sequencing changed that: by reading DNA directly from a sample, researchers could census entire communities without culturing anything. The Human Microbiome Project and its successors mapped the microbial geography of healthy bodies, and the results were humbling. No two people share the same microbiome. The same person varies over time. And "healthy" is not a single composition but a range of diverse, resilient communities — more like a rainforest than a recipe.
That diversity is the point. A diverse microbiome is a resilient one: it resists invasion by pathogens, digests a wide range of foods, and maintains the gut barrier that keeps microbes and their products where they belong. When diversity collapses — after heavy antibiotics, on a diet of ultra-processed food, in chronic disease — the ecosystem becomes fragile. Pathogens exploit the gaps. Inflammation rises. The barrier leaks. This is not a metaphor. It is measurable, in microbial counts, in metabolites, in immune markers, in clinical outcomes.
The most captivating corner of microbiome science is the gut-brain axis — the bidirectional communication between the gut and the brain via the vagus nerve, the immune system, hormones and microbial metabolites. The evidence that this axis matters is now strong in animals and growing in humans. Germ-free mice, raised without any microbes, show altered brain development, exaggerated stress responses and abnormal behaviour; colonising them with microbes normalises some of these traits — but only if done early, suggesting critical windows. In humans, differences in gut composition have been associated with depression, anxiety, autism, Parkinson's and Alzheimer's — associations that are real, replicated in some cases, and almost entirely unexplained in causal terms.
The mechanism candidates are concrete. Microbes produce short-chain fatty acids (SCFAs) — butyrate, propionate, acetate — by fermenting dietary fibre, and these molecules nourish gut cells, modulate immunity and cross into circulation. They produce or influence neurotransmitters: most of the body's serotonin is made in the gut; gut bacteria produce GABA, dopamine precursors and other neuroactive compounds. They modulate the immune system, whose inflammatory signals reach the brain. And they interact with the vagus nerve, the direct electrical hotline between gut and brainstem. Each mechanism is plausible. Each has some evidence. None, on its own, explains a psychiatric disorder.
This is where the hype outruns the science. Headlines announce that a probiotic "treats depression" or that gut bacteria "cause autism" on the basis of a single small study, usually in mice, usually correlational. The honest state of play is: the gut-brain axis is real, its clinical exploitation is mostly future, and the path from association to therapy runs through the same gauntlet as every other medical claim — replication, mechanism, randomised trials with clinical endpoints, and safety. The brain is the most protected organ in the body. The idea that yoghurt will rewire it is not science. It is marketing wearing a lab coat.
There is one microbiome therapy that works so dramatically it changed medicine: faecal microbiota transplantation for recurrent Clostridioides difficile infection. C. difficile is a bacterium that devastates the gut after antibiotics have wiped out the normal community, causing relentless diarrhoea that can kill. FMT — transferring processed stool from a healthy donor into the patient's gut — cures the infection in the large majority of cases where antibiotics have failed, by restoring the ecosystem that keeps C. difficile in check. It is ecological medicine in its purest form: not a drug targeting a pathogen, but a community restoring balance.
FMT's success has inspired trials for everything from ulcerative colitis to obesity to autism to cancer immunotherapy response. Some show genuine promise — ulcerative colitis has seen real, if partial, benefit in trials; early studies suggest the microbiome influences whether a patient responds to cancer immunotherapy, opening the possibility of microbiome modulation as an adjunct to treatment. Most indications, however, remain experimental. FMT carries real risks — transmission of pathogens, transfer of unknown traits, long-term ecological consequences — which is why regulators have moved toward defined, screened, standardised products rather than DIY stool transplants. The lesson of FMT is not "stool cures everything." It is that ecology can be medicine when the ecology, the indication and the evidence align.
The same caution applies to probiotics, the commercial face of microbiome science. The probiotic market is worth tens of billions, built on promises that mostly exceed the evidence. Systematic reviews find that for most healthy people, most probiotics do little measurable good — the strains pass through without colonising, and the gut returns to baseline. For specific conditions — antibiotic-associated diarrhoea, some infant colic, pouchitis — specific strains have real evidence. But "probiotic" is not a single thing. It is a category covering thousands of strains with different properties, and a claim for one strain is not a claim for another. The regulatory gap, in which probiotics are sold as foods or supplements with minimal proof, is where hype thrives.
Beyond the microbiome lies the broader biological revolution: synthetic biology — the engineering of living systems. Scientists now design genetic circuits, reprogram microbes to produce insulin, biofuels, materials and medicines, and build minimal genomes from scratch. CRISPR gene editing, adapted from a bacterial immune system, lets researchers cut and rewrite DNA with a precision that was science fiction a generation ago. Gene drives could, in principle, suppress malaria-carrying mosquitoes by spreading sterility through wild populations. Engineered microbes could clean pollutants, fix nitrogen without fertiliser, or manufacture proteins without animals.
The power is real, and so are the risks. The same tools that engineer a microbe to produce medicine could engineer one to cause harm. Gene drives released into the wild cannot easily be recalled. Engineered organisms interact with ecosystems in ways that are hard to predict. This is why synthetic biology is paired with governance — biosafety levels, screening of DNA synthesis orders, international norms, and in some cases moratoriums — and why the debate about it is not anti-science but pro-science: the field's own leaders have repeatedly called for guardrails, precisely because they understand the power of what they have built.
Meanwhile, the older biology — ecology, evolution, natural history — is delivering its own urgent message. Species are vanishing at rates not seen since the asteroid that killed the dinosaurs, driven by habitat loss, climate change, pollution and overexploitation. Biodiversity is not a luxury. It is the raw material of the microbiome, of medicine (half of modern drugs derive from natural products), of pollination, of the ecosystems that make the planet habitable. Every extinct species is a library burned before it was read. The microbiome revolution and the extinction crisis are the same story told at two scales: life is an interconnected system, and we are inside it, not above it.
Three falsifiers. If large, well-controlled trials showed a specific probiotic strain durably colonising the gut and improving a clinical endpoint, the probiotic scepticism would need revision for that strain and that endpoint. If germ-free and colonisation experiments showed no causal role for the microbiome in a disease where association is strong, the gut-brain claim for that disease would fail. If defined microbial consortia proved as effective as FMT for C. difficile with a better safety profile, the crude transplant would be retired — a welcome defeat. Science advances by such defeats as much as by victories.
Your microbiome is not a second brain. It is a partner — ancient, diverse, essential, and only partly understood. Treat it with the respect an ecosystem deserves: feed it fibre, spare it unnecessary antibiotics, distrust anyone selling a quick fix for it, and watch the trials, not the testimonials. The biology of the twenty-first century will be written in ecosystems, not in single genes or single microbes. We are only on the first page.
Through a Western lens, the microbiome is a biotech market: startups, patents, personalised nutrition.
Through an Eastern lens, it is a state science programme: large cohorts, traditional medicine re-examined through sequencing, scale.
Through a Global South lens, it is a public-health story: the microbiomes of the world's children are being shaped by antibiotics, ultra-processed food and sanitation — and the trials that matter most are the ones run where the burden is greatest. The microbes do not care about the lens. The policies built on them should.
For most healthy people, evidence for general benefit is weak. Systematic reviews find that for most healthy people most probiotics do little measurable good, because the strains pass through without colonising and the gut returns to baseline. For specific conditions, specific strains have real evidence — strain and condition matter, and 'probiotic' is not one thing.
Yes, via the vagus nerve, immune signals, hormones and microbial metabolites. Microbes produce short-chain fatty acids by fermenting dietary fibre, and influence neurotransmitters — most of the body's serotonin is made in the gut — but no single mechanism explains a psychiatric disorder. Associations with psychiatric and neurological disease are not yet proven causes, and probiotic 'cures' for brain disorders are not established.
For recurrent C. difficile under medical supervision with screened donors, benefit strongly outweighs risk. The transplant cures the infection in the large majority of cases where antibiotics have failed, by restoring the ecosystem that keeps C. difficile in check, but it carries real risks of pathogen transmission. For other uses it remains experimental, and DIY transplants are dangerous.
